Form 4: Amicus Therapeutics Director Receives Significant Equity Compensation Grant

Amicus Therapeutics, Inc. Director Burke W. Whitman was granted 20,414 Restricted Stock Units and 74,872 stock options as part of his compensation.

Summary

• Burke W. Whitman, a Director of Amicus Therapeutics, Inc. (FOLD), reported the acquisition of equity securities on June 5, 2025.
• The acquisition includes 20,414 shares of Common Stock in the form of Restricted Stock Units (RSUs), granted at a price of $0.0 per share.
• These RSUs will vest in full on the one-year anniversary of the grant date, with each RSU equivalent to one share of Amicus common stock.
• Additionally, Mr. Whitman was granted 74,872 stock options with an exercise price of $5.96 per share.
• These stock options will vest and become exercisable 100% on the one-year anniversary of the grant date and have an expiration date of June 5, 2035.
• Following these transactions, Mr. Whitman beneficially owns 118,598 shares of Common Stock directly and 74,872 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of equity compensation to a director is generally viewed positively as it aligns the director's financial interests with the long-term performance of the company and its shareholders. It is a routine compensation event.

Positives

• The grant of Restricted Stock Units and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a common practice to attract and retain experienced board members.

Future Outlook

The granted Restricted Stock Units and stock options are subject to a one-year vesting period from the grant date, meaning they will become fully vested and exercisable on June 5, 2026. The stock options have a long-term expiration date of June 5, 2035.

Industry Context

Equity compensation, including RSUs and stock options, is a standard practice across various industries, particularly in biotechnology and pharmaceuticals like Amicus Therapeutics, to incentivize and retain key personnel, including directors, by linking their financial interests to the company's long-term stock performance.

Comparison to Industry Standards

• The grant of equity compensation to non-employee directors is a common and widely accepted practice in corporate governance across global markets, including the U.S. biotech sector.
• The structure of RSUs vesting over one year and options with a 10-year term is typical for director compensation packages, aiming to align long-term interests.
• Comparable companies in the biotechnology sector often utilize similar equity-based incentives for their board members to ensure alignment with shareholder value creation.

Related Party Transactions

• The grant of 20,414 Restricted Stock Units and 74,872 stock options to Burke W. Whitman, a Director of Amicus Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making focused on stock performance.
• Employees: While not directly impacting employees, such compensation practices can set precedents for executive and director remuneration within the company.

Next Steps

• The Restricted Stock Units and stock options are expected to vest on June 5, 2026, one year after the grant date.

Key Dates

Keywords

Amicus Therapeutics, FOLD, Burke W. Whitman, Director, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Corporate Governance